Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 144

Similar articles for PubMed (Select 19393837)

1.

Janus kinase mutations.

Levine RL.

Semin Oncol. 2009 Apr;36(2 Suppl 1):S6-11. doi: 10.1053/j.seminoncol.2009.02.005.

PMID:
19393837
2.

Mechanisms of mutations in myeloproliferative neoplasms.

Levine RL.

Best Pract Res Clin Haematol. 2009 Dec;22(4):489-94. doi: 10.1016/j.beha.2009.08.006. Review.

PMID:
19959098
3.

New JAK2 inhibitors for myeloproliferative neoplasms.

Quintás-Cardama A, Verstovsek S.

Expert Opin Investig Drugs. 2011 Jul;20(7):961-72. doi: 10.1517/13543784.2011.579560. Epub 2011 Apr 27. Review.

PMID:
21521147
4.

Therapeutic potential of JAK2 inhibitors.

Verstovsek S.

Hematology Am Soc Hematol Educ Program. 2009:636-42. doi: 10.1182/asheducation-2009.1.636. Review.

5.

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL.

PLoS Med. 2006 Jul;3(7):e270.

6.

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?

Tibes R, Mesa RA.

Leuk Lymphoma. 2011 Jul;52(7):1178-87. doi: 10.3109/10428194.2011.566952. Epub 2011 May 23. Review.

PMID:
21599574
7.

Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.

Tibes R, Bogenberger JM, Benson KL, Mesa RA.

Mol Diagn Ther. 2012 Oct;16(5):269-83. doi: 10.1007/s40291-012-0006-3. Review.

PMID:
23023734
8.

JAK-mutant myeloproliferative neoplasms.

Levine RL.

Curr Top Microbiol Immunol. 2012;355:119-33. doi: 10.1007/82_2011_170. Review.

PMID:
21823028
9.

[Evaluation of V617F mutation of JAK2 in negative chromosome Philadelphia chronic myeloproliferative disorders].

Remacha AF, Puget G, Nomdedéu JF, Estivill C, Sardà MP, Canals C.

Med Clin (Barc). 2006 Oct 28;127(16):601-4. Spanish.

PMID:
17145024
10.

Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.

Levine RL, Wernig G.

Hematology Am Soc Hematol Educ Program. 2006:233-9, 510. Review.

11.

Myeloproliferative disorders.

Levine RL, Gilliland DG.

Blood. 2008 Sep 15;112(6):2190-8. doi: 10.1182/blood-2008-03-077966. Review.

12.

JAK and MPL mutations in myeloid malignancies.

Tefferi A.

Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360. Review.

PMID:
18297515
13.

[Myeloproliferative diseases caused by JAK2 mutation].

Nagata K, Shimoda K.

Rinsho Byori. 2009 Apr;57(4):357-64. Review. Japanese.

PMID:
19489438
14.

Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.

Passamonti F, Maffioli M, Caramazza D, Cazzola M.

Oncotarget. 2011 Jun;2(6):485-90.

15.
16.
17.

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].

Iványi JL, Marton E, Plander M.

Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226. Hungarian.

PMID:
22011365
18.

Kinase drug discovery approaches in chronic myeloproliferative disorders.

Kumar C, Purandare AV, Lee FY, Lorenzi MV.

Oncogene. 2009 Jun 18;28(24):2305-13. doi: 10.1038/onc.2009.107. Epub 2009 May 4. Review.

PMID:
19421140
19.

Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.

Quintás-Cardama A, Verstovsek S.

Cancer. 2012 Feb 15;118(4):870-7. doi: 10.1002/cncr.26359. Epub 2011 Jul 15.

20.

JAK2 mutations and clinical practice in myeloproliferative neoplasms.

Tefferi A.

Cancer J. 2007 Nov-Dec;13(6):366-71. Review.

PMID:
18032973
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk